LONDON (Alliance News) - Niche pharmaceuticals development firm Quantum Pharma PLC on Wednesday said its Colonis division has launched its Glycopyrronium Bromide Oral Solution.
The product is used as an add-on therapy for people suffering with peptic ulcers, which occur on the lining of the stomach.
"We are pleased to announce the launch of our Glycopyrronium Bromide solution. This is the first licensed presentation of this product in the UK and marks further progress in our strategy to deliver unlicensed to licensed and other niche products to the market," said Chris Rigg, Quantum's chief financial officer and acting chief executive.
Quantum shares were up 2.7% to 77.01 pence Wednesday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
